Fertility and Sterility
Volume 93, Issue 4 , Pages 1215-1219 , 1 March 2010

Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels

Received 12 October 2008 ,Revised 27 November 2008 ,Accepted 8 December 2008.

References 

  1. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559–577
  2. Ovarian hyperstimulation syndrome. The Practice Committee of the American Society for Reproductive Medicine. Fertil Steril. 2006;86:S178–S183
  3. ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–5
  4. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56:213–220
  5. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Short communication. Hum Reprod. 2000;15:1965–1968
  6. Kol SK. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81:1–5
  7. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86:1682–1687
  8. Hernández ER, Gomez JL, Ricciarelli E. No room for cancellation, coasting or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril. Published online 12 June 2008 [Epub ahead of print].
  9. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–1
  10. Gómez-Palomares JL, Acevedo-Martín B, Andrés L, Ricciarelli E, Hernández ER. LH improves early follicular recruitment in women over 38 years old. Reprod Biomed Online. 2005;11:409–414
  11. Palermo GP, Joris H, Devroey P, Van Steirteghem AC. Pregnancy after intracytoplasmatic injection of a single spermatozoon into an oocyte. Lancet. 1992;340:17–18
  12. Veeck LL. Atlas of Human Gametes and Conceptuses. New York: Parthenon Publishing Group; 1999;
  13. Humaidan P, Ejdrup Bredkjaer H, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–1220
  14. Kolibianakis EM, Schultze-Mosgau A, Schroder A, van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocytes maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887–2892
  15. Griesinger G, Diedrich K, Devroey P, Koliobinakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159–168
  16. Griesinger G, Koliobinakis EM, Papanikolaou EG, Diedrich K, Van Steirteghem A, Devroey P, et al. Triggering of final oocyte maturation with gonadotropins-releasing agonist or human chorionic gonadotropins. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril. 2007;88:616–621

 M.A.M. has nothing to disclose. J.L.G.-P. has nothing to disclose. E.R. has nothing to disclose. E.R.H. has nothing to disclose.

PII: S0015-0282(08)04659-1

doi: 10.1016/j.fertnstert.2008.12.019

Fertility and Sterility
Volume 93, Issue 4 , Pages 1215-1219 , 1 March 2010

Article Tools